Fate Therapeutics (FATE) Equity Average (2016 - 2025)
Historic Equity Average for Fate Therapeutics (FATE) over the last 13 years, with Q3 2025 value amounting to $247.7 million.
- Fate Therapeutics' Equity Average fell 3475.24% to $247.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.7 million, marking a year-over-year decrease of 3475.24%. This contributed to the annual value of $343.6 million for FY2024, which is 1938.31% down from last year.
- As of Q3 2025, Fate Therapeutics' Equity Average stood at $247.7 million, which was down 3475.24% from $274.9 million recorded in Q2 2025.
- Over the past 5 years, Fate Therapeutics' Equity Average peaked at $771.1 million during Q2 2021, and registered a low of $247.7 million during Q3 2025.
- Over the past 5 years, Fate Therapeutics' median Equity Average value was $457.6 million (recorded in 2023), while the average stood at $485.1 million.
- Its Equity Average has fluctuated over the past 5 years, first soared by 15313.14% in 2021, then plummeted by 3475.24% in 2025.
- Over the past 5 years, Fate Therapeutics' Equity Average (Quarter) stood at $704.6 million in 2021, then decreased by 28.9% to $501.0 million in 2022, then dropped by 23.03% to $385.6 million in 2023, then fell by 11.69% to $340.5 million in 2024, then dropped by 27.26% to $247.7 million in 2025.
- Its Equity Average was $247.7 million in Q3 2025, compared to $274.9 million in Q2 2025 and $303.6 million in Q1 2025.